Literature DB >> 26894600

Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia.

Zare-Abdollahi Davood1, Safari Shamsi1, Hamid Ghaedi1, Riazi-Isfahani Sahand2, Ghadyani Mojtaba1, Tabarraee Mahdi1, Mirfakhraie Reza1, Mohammad Javad Ebrahimi1, Reyhaneh Sadat Miri-Moosavi3, Sara Boosaliki1, Omrani Mir Davood4.   

Abstract

In acute myeloid leukemia (AML), despite the acceptance of standard intensive chemotherapy as an optimal induction regimen for all age groups, in the elderly patients, the best treatment should meet the challenge of multiple factors like age, comorbidities, and cytogenetics, making them ineligible for standard induction chemotherapy. Using the current low-intensity therapies like decitabine, azacitidine, and low-dose cytarabine as a single arm, outcomes for these patients remain poor. As a histone deacetylase inhibitor valproic acid (VPA) exhibit anticancer activity by triggering apoptosis, the mechanism of which is not yet completely clarified. To explore the possible connection between VPA treatment and the Hippo pathway as an apoptosis stimulating route, we also explore the expression of major components of this pathway and for the first time we postulate a relationship between VPA treatment and cell death induction through RASSF1A expression induction. Furthermore, we demonstrate that autophagy inhibition by chloroquine (CQ) significantly augmented the cytotoxic effect of VPA on AML cells, especially in those with unfavorable and normal karyotype. Regarding that VPA and CQ are well-tolerated drugs and our presumptive results of usefulness of VPA + CQ in three cytogenetic risk groups of AML, this combinatorial therapy could represent an attractive treatment option for older AML patients unfit for intensive therapy.

Entities:  

Keywords:  AML; ATG7; Acute myeloid leukemia; Apoptosis; Autophagy; BECN1; Cytogenetics; HDAC; MST1; MST2; RASSF1A; VPA, chloroquine; Valproic acid

Mesh:

Substances:

Year:  2016        PMID: 26894600     DOI: 10.1007/s13277-016-4985-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

1.  Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARα oncoprotein.

Authors:  Zhuo Wang; Lizhi Cao; Rui Kang; Minghua Yang; Liying Liu; Yiming Zhao; Yan Yu; Min Xie; Xiaocheng Yin; Kristen M Livesey; Daolin Tang
Journal:  Autophagy       Date:  2011-04-01       Impact factor: 16.016

2.  Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.

Authors:  Jean-Pierre Issa; Guillermo Garcia-Manero; Xuelin Huang; Jorge Cortes; Farhad Ravandi; Elias Jabbour; Gautam Borthakur; Mark Brandt; Sherry Pierce; Hagop M Kantarjian
Journal:  Cancer       Date:  2014-10-21       Impact factor: 6.860

Review 3.  Targeting autophagy during cancer therapy to improve clinical outcomes.

Authors:  Jean M Mulcahy Levy; Andrew Thorburn
Journal:  Pharmacol Ther       Date:  2011-03-23       Impact factor: 12.310

4.  Treating the elderly patient with acute myelogenous leukemia.

Authors:  Selina M Luger
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

Review 5.  Which Acute Myeloid Leukemia Patients Should Be Offered Transplantation?

Authors:  Eolia Brissot; Mohamad Mohty
Journal:  Semin Hematol       Date:  2015-03-17       Impact factor: 3.851

6.  Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia.

Authors:  Gesine Bug; Kerstin Schwarz; Claudia Schoch; Manuela Kampfmann; Reinhard Henschler; Dieter Hoelzer; Oliver G Ottmann; Martin Ruthardt
Journal:  Haematologica       Date:  2007-04       Impact factor: 9.941

7.  Intact expression status of RASSF1A in acute myeloid leukemia.

Authors:  Davood Zare-Abdollahi; Shamsi Safari; Abolfazl Movafagh; Mojtaba Ghadiani; Sahand Riazi-Isfahani; Mir Davood Omrani
Journal:  Med Oncol       Date:  2013-11-19       Impact factor: 3.064

8.  Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid.

Authors:  Andrea Kuendgen; Gesine Bug; Oliver G Ottmann; Detlef Haase; Julie Schanz; Barbara Hildebrandt; Kathrin Nachtkamp; Judith Neukirchen; Ariane Dienst; Rainer Haas; Ulrich Germing; Norbert Gattermann
Journal:  Clin Epigenetics       Date:  2011-04-08       Impact factor: 6.551

9.  RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein.

Authors:  David Matallanas; David Romano; Karen Yee; Katrin Meissl; Lucia Kucerova; Daniela Piazzolla; Manuela Baccarini; J Keith Vass; Walter Kolch; Eric O'neill
Journal:  Mol Cell       Date:  2007-09-21       Impact factor: 17.970

10.  The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia.

Authors:  Hanne Fredly; Elisabeth Ersvær; Astrid Olsnes Kittang; Galina Tsykunova; Bjørn Tore Gjertsen; Oystein Bruserud
Journal:  Clin Epigenetics       Date:  2013-08-01       Impact factor: 6.551

View more
  6 in total

1.  Transcriptional Modulation of the Hippo Signaling Pathway by Drugs Used to Treat Bipolar Disorder and Schizophrenia.

Authors:  Bruna Panizzutti; Chiara C Bortolasci; Briana Spolding; Srisaiyini Kidnapillai; Timothy Connor; Mark F Richardson; Trang T T Truong; Zoe S J Liu; Gerwyn Morris; Laura Gray; Jee Hyun Kim; Olivia M Dean; Michael Berk; Ken Walder
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

2.  miR-7977 inhibits the Hippo-YAP signaling pathway in bone marrow mesenchymal stromal cells.

Authors:  Masahiro Yoshida; Hiroto Horiguchi; Shohei Kikuchi; Satoshi Iyama; Hiroshi Ikeda; Akari Goto; Yutaka Kawano; Kazuyuki Murase; Kohichi Takada; Koji Miyanishi; Junji Kato; Masayoshi Kobune
Journal:  PLoS One       Date:  2019-03-05       Impact factor: 3.240

Review 3.  Role of HDACs in normal and malignant hematopoiesis.

Authors:  Pan Wang; Zi Wang; Jing Liu
Journal:  Mol Cancer       Date:  2020-01-07       Impact factor: 27.401

Review 4.  Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia-Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation.

Authors:  Øystein Bruserud; Galina Tsykunova; Maria Hernandez-Valladares; Hakon Reikvam; Tor Henrik Anderson Tvedt
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-02

5.  Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.

Authors:  Ida Sofie Grønningsæter; Hanne Kristin Fredly; Bjørn Tore Gjertsen; Kimberley Joanne Hatfield; Øystein Bruserud
Journal:  Cells       Date:  2019-10-10       Impact factor: 6.600

Review 6.  Epigenetic Control of Autophagy in Cancer Cells: A Key Process for Cancer-Related Phenotypes.

Authors:  Paul Peixoto; Céline Grandvallet; Jean-Paul Feugeas; Michaël Guittaut; Eric Hervouet
Journal:  Cells       Date:  2019-12-17       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.